A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT07006597
Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 300 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from electronic medical records (EMR). Patient reported and eCRF data will be linked via a unique ID and PIN assigned to each participant at enrolment.
Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Traditional site recruitment (all countries):
Adult patients who are being treated for CIDP at one of the participating clinics or centers in one of the participating countries (the US, UK or Germany) at the time of enrolment and who meet the inclusion and exclusion criteria will be identified, approached by their clinical team and invited to participate in the registry.
Patient-reported data will be collected via the VRCIDP Registry platform, a digital data capture platform accessible via a web-enabled platform on a connected device (e.g., smartphone, tablet, laptop, computer). Custom survey and patient-reported outcomes data will be collected at baseline and at regular intervals thereafter for a follow-up period of up to 10 years. The data collected will capture the impact of CIDP on daily living, fatigue, and health-related quality of life.
Site research teams will complete and update an electronic case report form (eCRF every six months ± one month for each patient, including data from the patient's EMR. eCRFs that are completed within one months prior to or following each six-month period will be considered within the same assessment window for analytics purposes. This ensures that patients will not be required to visit the clinical site for the purposes of the registry outside of their regular clinical visits.
Community neurologist recruitment (US only):
Community neurologists who are treating CIDP patients who would be eligible for participation in the registry will be able to register their interest for involvement and provide details of their credentials via an informational website. Approved community neurologists will identify and approach potential participants, who will participate in the registry as normal. Vitaccess will partner with a third-party organization with EMR aggregator capabilities to capture data from participants' existing medical records to match eCRF outputs.
Direct-to-patient recruitment (US only):
The direct-to-patient recruitment approach will involve patients directly registering their interest for participating in the registry. Awareness of the study will be raised via collaborations with patient advisory group(s) (PAGs), who may utilize their existing relationships with CIDP patients to inform them of the study, for example via their social media. Likewise, Vitaccess may utilize social media to advertise the study directly to patients. Recruitment/promotional materials will be created for the purpose of sharing on social media platforms. As with recruitment via community neurologists, existing EMR data will be captured for consenting participants by a third-party organization with EMR aggregator capabilities.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
None
Time frame: 10 years
A patient registry designed to build a repository of data containing disease characteristics at onset, disease progression, treatment and outcomes in CIDP [(i.e., its treatment and impact on symptoms, daily activities, and quality of life (QoL)] from patients, HCPs, and existing medical records.
Time frame: At baseline
EMR data reported by HCPs or captured via EMR aggregators ("Registration Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Clinical Trial Participation Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Diagnosis Information Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Clinical Characteristics Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Medical History Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Concomitant non-CIDP medications log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Routine CIDP medication log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Rescue CIDP Treatments Log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Healthcare Resource Use")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Adverse Events Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Caregiver Information Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Family History Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Employment Status Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Health Insurance Status Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Disease History")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Clinical Investigations")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
EMR data reported by HCPs or captured via EMR aggregators ("Management Decisions by Treating Neurologist", "Health System Implications on Treatment", "Patient Choice on Treatment Decisions", "Tools used for Therapeutic Decisions")
Time frame: At baseline and every 6 months thereafter for up to 10 years.
"Chronic Acquired Polyneuropathy patient-reported index (CAP-PRI)" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline and every 6 months thereafter for up to 10 years.
"Work Productivity and Activity Impairment (WPAI)" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 3 months thereafter for up to 10 years.
"EQ-5D-5-level version (EQ-5D-5L)" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 6 months thereafter for up to 10 years.
"NeuroQoL Fatigue Short Form" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 6 months thereafter for up to 10 years.
"Perceived Stress Fixed Form" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 6 months thereafter for up to 10 years.
"PROMIS Neuropathic Pain Quality 5a" and "PROMIS Pain Intensity 3a" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 6 months thereafter for up to 10 years.
"Hospital Anxiety and Depression Scale (HADS)" data reported by patients via the Vitaccess Real CIDP Registry platform
Time frame: At baseline visit and every 6 months thereafter for up to 10 years.
"Patient global impression of change (PGIC)" data reported by patients via the Vitaccess Real CIDP Registry platform
Contact information is provided by the study sponsor or research team.
Vitaccess Ltd
Industry
Vitaccess Real CIDP Registry: A Prospective International Observational Patient Registry in Chronic Inflammatory Demyelinating Polyneuropathy Linking Clinical and Patient-Reported Data
Acronym: VRCIDP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07091630
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Birmingham, Alabama, United States
View Trial DetailsNCT06920004
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Birmingham, Alabama, United States
View Trial DetailsNCT00716066
Autoimmune Disease, Autoimmune Diseases
Denver, Colorado, United States
View Trial DetailsNCT07188844
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
New Haven, Connecticut, United States
View Trial Details